Chronic Myelogenous Leukemia — New Concepts

Publisher Website
Google Scholar
Abstract
CHRONIC myelogenous leukemia (CML) is a clonal myeloproliferative disorder arising from neoplastic transformation at the level of the pluripotent stem cell and characterized clinically by a marked overproduction of granulocytes. The disease was probably first identified in 1845 by Craigie,1 Bennett,2 and Virchow,3 who called attention to the prominent splenomegaly and "suppuration of the blood." In 1960, Nowell and Hungerford described an abnormal, small chromosome (the Philadelphia, or Ph1, chromosome) in patients with this disorder.4 Because of the typical clinical picture and the specific chromosomal abnormality, CML is perhaps the best defined of the myeloproliferative disorders. In western countries, . . .